Answers are grounded in this paper and cite their sources.
IntroductIonHyperglycemia is frequently observed metabolic abnormality in a critical care setting.Observational studies have shown that admission hyperglycemia is associated with higher mortality and morbidity.[1] The stress hyperglycemia was considered to be a beneficial response previously, to provide excess fuel to the tissues.[2] However, the concepts of hyperglycemia in the Intensive Care Units (ICUs) were revolutionized by Leuwen et al., who showed beneficial effects of intensive glucose control in a group of patients admitted to surgical ICU.[3] Subsequent studies from the same group and others did not show a similar trend, which generated a lot of debate in the past decade.[4] The debate was laid to rest by NICE-SUGAR study and the majority of the researchers now agree that good glycemic control is beneficial and intensive control may be useful in only select situations.[5,6] The controversy over the management of hyperglycemia in ICU extends beyond hyperglycemia into selecting the ideal therapeutic option.[7] Insulin remains the cornerstone in the management of critically ill patients.However, hypoglycemia remains a major limiting factor for the intensive insulin therapy and is an independent predictor of mortality.[8] During the past decade, several new drugs have been approved for the management of type 2 diabetes mellitus (T2DM).A few of them have revolutionized the management of T2DM and its complications.Incretin modulators are a group of antidiabetic drugs which increase the endogenous glucagon-like peptide-1 (GLP-1) levels.[9] They include the GLP-1 analogs (liraglutide and exenatide) and enhancers (gliptins).Liraglutide is a long-acting GLP-1 analog used in T2DM and has even shown to be beneficial in preventing cardiovascular deaths. Background: Intravenous insulin is the cornerstone in the management of hyperglycemia in the Intensive Care Unit (ICU).We studied the efficacy of liraglutide compared with insulin in the ICU.Materials and Methods: In this prospective, open-labeled, randomized study, we included 120 patients (15-65 years, either sex) admitted to ICU with capillary blood glucose (CBG) between 181 and 300 mg/dl.We excluded patients with secondary diabetes and APACHE score >24.The patients were divided into two groups (n = 60) based on the CBG: Group 1 (181-240) and Group 2 (241-300).They were randomized further into four subgroups (n = 30) to receive insulin (Groups 1A and 2A), liraglutide (Group 1B), and insulin with liraglutide (Group 2B).The primary outcome was the ability to achieve CBG below 180 mg/dL at the end of 24 h.The secondary outcomes include mortality at 1 month and hospital stay.Data and results were analyzed using Mann-Whitney U-test, paired t-test, and Chi-square tests.Results: The mean age of the patients (93M and 27F) was 57.1 ± 13.9 years, hospital stay (16.9 ± 7.5 days), and CBG was 240.5 ± 36.2 mg/dl.The primary outcome was reached in 26, 27, 25, and 28 patients of Groups 1A, 2A, 1B, and 2B, respectively.The 30-day mortality and hospital stay were similar across all the four groups.Hypoglycemia was common with insulin and gastrointestinal side effects were more common with liraglutide (P < 0.001).Conclusion: Liraglutide is a viable alternative to insulin for glycemic control in the ICU.Further studies with a larger number of patients are required to confirm our findings.
No takes yet. Share an insight, caveat, or question.
Singh et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: